Silexion Therapeutics Receives German Regulatory Approval for Phase 2/3 Pancreatic Cancer Trial Design
Key Insights
Silexion Therapeutics (search) received formal written Scientific Advice from Germany's BfArM supporting the design of its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer (search).
The positive regulatory feedback covers clinical design, dosing plans, patient population strategy, and manufacturing considerations for the RNA interference therapy targeting KRAS-driven cancers (search).
The company plans to complete regulatory submissions in Israel by end of Q4 2025 and in Germany during Q1 2026, with Phase 2/3 trial initiation targeted for the first half of 2026.
Silexion Therapeutics (search) Corp. (NASDAQ: SLXN) announced it has received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices (search) (BfArM) regarding the proposed design of its planned Phase 2/3 clinical trial for SIL204, the company's lead RNA interference therapy for locally advanced pancreatic cancer (search). The guidance provides significant regulatory clarity as the clinical-stage biotechnology company prepares its Phase 2/3 clinical trial submissions.
Regulatory Milestone Supports Trial Design
The positive response from BfArM represents an important milestone supporting the acceptability of the proposed Phase 2/3 study design, based on supporting safety data and manufacturing specifications. The written feedback covers several core components of the program, including clinical design, dosing plans, patient population strategy, nonclinical support, and CMC/manufacturing considerations.
"This written Scientific Advice represents a meaningful step in our regulatory path and provides us with the supporting clarity needed to finalize our Phase 2/3 submission packages," said Ilan Hadar, Chairman and Chief Executive Officer of Silexion. "SIL204 continues to progress on schedule, and the engagement with BfArM supports the momentum we have built heading into 2026."
Timeline for Regulatory Submissions and Trial Initiation
The feedback will be incorporated into Silexion's upcoming regulatory submissions in Israel, which are expected by the end of 2025, and in Germany, which are expected during the first quarter of 2026. Silexion remains on track to initiate its Phase 2/3 clinical trial of SIL204 in the first half of 2026, pending regulatory clearance.
The company continues to advance all other operational and development activities required for trial launch, including manufacturing readiness, toxicology data integration, and clinical site preparations.
Targeting KRAS-Driven Cancers
Silexion Therapeutics (search) is developing innovative treatments for solid tumor cancers (search) with the mutated KRAS (search) oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone.
Hadar emphasized the therapeutic potential, stating that the company remains "highly focused on bringing SIL204 into the clinic and advancing a therapy that we believe has the potential to address critical unmet needs in KRAS-mutated cancers (search)."
Company Background
Silexion Therapeutics (search) is a clinical-stage, oncology-focused biotechnology company dedicated to developing treatments for unsatisfactorily treated solid tumor cancers (search) with mutated KRAS (search) oncogenes. The company is committed to advancing therapeutic developments in oncology, with particular focus on its lead product candidate for locally advanced pancreatic cancer (search).